X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
cd138 (202) 202
humans (157) 157
index medicus (127) 127
multiple myeloma (80) 80
syndecan-1 (79) 79
female (77) 77
male (68) 68
expression (63) 63
pathology (63) 63
immunohistochemistry (61) 61
middle aged (61) 61
oncology (58) 58
cancer (48) 48
aged (47) 47
syndecan-1 - metabolism (46) 46
flow cytometry (44) 44
hematology (43) 43
adult (41) 41
multiple-myeloma (39) 39
prognosis (39) 39
animals (33) 33
plasma cells (30) 30
research (29) 29
multiple myeloma - pathology (28) 28
aged, 80 and over (26) 26
mice (25) 25
analysis (24) 24
diagnosis (23) 23
tumors (23) 23
bone-marrow (22) 22
cell line, tumor (22) 22
plasma-cells (22) 22
syndecans (22) 22
bone marrow (21) 21
immunology (21) 21
plasma cells - immunology (21) 21
plasma cells - pathology (21) 21
hemic and lymphatic diseases (20) 20
lymphomas (20) 20
survival (20) 20
carcinoma (18) 18
immunophenotyping (18) 18
multiple myeloma - metabolism (18) 18
phenotype (18) 18
antibodies (17) 17
lymphoma (17) 17
syndecan-1 - analysis (17) 17
antigens (15) 15
bone marrow - pathology (15) 15
cell biology (15) 15
cells (15) 15
differentiation (15) 15
disease (15) 15
immune system diseases (15) 15
myeloma (15) 15
plasma (15) 15
plasma cell (15) 15
syndecan-1 - genetics (15) 15
syndecan-1 - immunology (15) 15
gene expression regulation, neoplastic (14) 14
immunoglobulins (14) 14
multiple myeloma - diagnosis (14) 14
multiple myeloma - immunology (14) 14
plasma cells - metabolism (14) 14
care and treatment (13) 13
cd138/syndecan-1 (13) 13
cd38 (13) 13
chemotherapy (13) 13
gene expression (13) 13
heparan-sulfate proteoglycans (13) 13
biomarkers, tumor - metabolism (12) 12
biopsy (12) 12
cell differentiation (12) 12
cell proliferation (12) 12
leukemia (12) 12
prognostic-significance (12) 12
apoptosis (11) 11
b-lymphocytes - immunology (11) 11
development and progression (11) 11
health aspects (11) 11
immunotherapy (11) 11
membrane glycoproteins - analysis (11) 11
radioimmunotherapy (11) 11
syndecan (11) 11
syndecan‐1 (11) 11
treatment outcome (11) 11
young adult (11) 11
article (10) 10
b-lymphocytes - pathology (10) 10
breast cancer (10) 10
breast-cancer (10) 10
cd20 (10) 10
diagnosis, differential (10) 10
growth (10) 10
kaplan-meier estimate (10) 10
lymphoma, b-cell - pathology (10) 10
lymphoma, large b-cell, diffuse - pathology (10) 10
medicine & public health (10) 10
proteoglycans - analysis (10) 10
retrospective studies (10) 10
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (256) 256
Russian (5) 5
French (4) 4
German (3) 3
Polish (2) 2
Chinese (1) 1
Japanese (1) 1
Portuguese (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Pathology, ISSN 0031-3025, 08/2018, Volume 50, Issue 5, pp. 581 - 584
Journal Article
American Journal of Clinical Pathology, ISSN 0002-9173, 2004, Volume 121, Issue 4, pp. 482 - 488
Journal Article
Molecular Oncology, ISSN 1574-7891, 03/2014, Volume 8, Issue 2, pp. 297 - 310
Reprogramming of NK cells with a chimeric antigen receptor (CAR) proved an effective strategy to increase NK cell reactivity and recognition specificity toward... 
NK cells | Chimeric antigen receptor | CD138 (syndecan-1) | Multiple myeloma | Adoptive immunotherapy | CD138 (syndecan‐1) | Humans | Middle Aged | Syndecan-1 - genetics | Neoplasm Proteins - immunology | Male | Multiple Myeloma - immunology | Killer Cells, Natural - pathology | Lymphocyte Activation - genetics | Lymphocyte Activation - immunology | Multiple Myeloma - therapy | Single-Chain Antibodies - genetics | Transfection | Syndecan-1 - immunology | Killer Cells, Natural - immunology | Adult | Female | Neoplasm Proteins - genetics | Antibodies, Neoplasm - immunology | Mice, SCID | Multiple Myeloma - pathology | Animals | Cell Line, Tumor | Mice, Inbred NOD | Antibodies, Neoplasm - genetics | Mice | Multiple Myeloma - genetics | Single-Chain Antibodies - immunology | Antigen-antibody reactions | Medical colleges | Antigens | Oncology, Experimental | Genes | Research | Biological response modifiers | Chemotherapy | Killer cells | Immunotherapy | Genetically modified organisms | Genetic research | Genetic aspects | Lymphomas | Cancer | Interferon gamma | Cell proliferation | Cytolytic activity | Plasma | Severe combined immunodeficiency | Leukemia | Radiation | Effector cells | Clinical trials | Cytotoxicity | Cell activation | Granzyme B | Xenografts | Bone marrow | Remission | Natural killer cells | Immunoglobulins | Secretion | Tumor cells | Cell division | Cell lines | Interferon | Females
Journal Article
European journal of immunology, ISSN 0014-2980, 11/2015, Volume 45, Issue 11, pp. 3045 - 3051
Invariant natural killer T ( i NKT) cells recognize glycolipids as antigens and diversify into NKT1 (IFN-γ), NKT2 (IL-4), and NKT17 (IL-17) functional subsets... 
Syndecan-1 | IFN-γ | CD138 | NKT17 | iNKT cells | IL-17
Journal Article
Cytometry Part B - Clinical Cytometry, ISSN 1552-4949, 01/2015, Volume 88, Issue 1, pp. 69 - 73
Journal Article
European Urology, ISSN 0302-2838, 2017, Volume 72, Issue 1, pp. 142 - 150
Journal Article
by Jiang, H and Zhang, WH and Shang, PP and Zhang, H and Fu, WJ and Ye, F and Zeng, TM and Huang, HJ and Zhang, XG and Sun, WP and Sze, DMY and Yi, Q and Hou, J
MOLECULAR ONCOLOGY, ISSN 1574-7891, 03/2014, Volume 8, Issue 2, pp. 297 - 310
Reprogramming of NK cells with a chimeric antigen receptor (CAR) proved an effective strategy to increase NK cell reactivity and recognition specificity toward... 
NK cells | Multiple myeloma | Adoptive immunotherapy | BONE-MARROW | TUMOR-CELLS | IDENTIFICATION | CYTOLYTIC ACTIVITY | Chimeric antigen receptor | MESSENGER-RNA | ONCOLOGY | CD138 (syndecan-1) | MOUSE MODEL | IN-VIVO | RECEPTORS | LINE NK-92
Journal Article
American Journal of Clinical Pathology, ISSN 0002-9173, 2004, Volume 121, Issue 2, pp. 254 - 263
We evaluated the immunohistochemical profile and specificity of CD138 reactivity in 238 specimens from hematopoietic and nonhematopoietic neoplasms. In 91 bone... 
Carcinoma | Sarcoma | Multiple myeloma | Plasma cells | Malignant lymphoma | Syndecan-1 | CD138 | MONOCLONAL-ANTIBODY B-B4 | multiple myeloma | CD138/SYNDECAN-1 | sarcoma | BONE-MARROW BIOPSIES | syndecan-1 | PATHOLOGY | plasma cells | EPITHELIAL MESENCHYMAL INTERACTIONS | carcinoma | SURFACE PROTEOGLYCAN | malignant lymphoma | EXPRESSION | ASSOCIATION | ANTIGEN | MYELOMA
Journal Article
Journal Article
Clinical Lymphoma, Myeloma and Leukemia, ISSN 2152-2650, 06/2019, Volume 19, Issue 6, pp. 372 - 380
Indatuximab ravtansine (BT062) is an antibody-drug conjugate that binds to CD138, which is overexpressed on multiple myeloma (MM) cells. We report from 2... 
Syndecan-1 | CD138 | Monoclonal antibody | Antibody-drug conjugate | Multiple-dose | CRITERIA | CELLS | ONCOLOGY | HEMATOLOGY
Journal Article
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, ISSN 0002-9173, 04/2004, Volume 121, Issue 4, pp. 482 - 488
Bone marrow aspirates from 306 patients with multiple myeloma were analyzed by flow cytometric immunophenotyping. The plasma cells (PCs) were identified by... 
MARROW | syndecan-1 | PATHOLOGY | PLASMA-CELLS | LYMPHOMAS | CELL PROLIFERATIVE DISORDERS | myeloma | immunophenotype | DISEASE | CD138 | flow cytometry | plasma cell | EXPRESSION | CD56 | BLOOD
Journal Article
Journal of Research in Medical and Dental Science, ISSN 2347-2545, 2017, Volume 5, Issue 2, pp. 21 - 25
Syndecan-1 (Sdc-1) is an important regulator of cell–cell and cell–extracellular matrix interactions. It is significantly involved in the carcinogenesis and... 
Basal cell carcinoma | Syndecan-1 (CD138) | Biological behaviour
Journal Article
Medicinskaâ Immunologiâ, ISSN 1563-0625, 03/2019
Plasma cells are often considered to be among important criteria in histological diagnosis of chronic endometritis (CE). Low plasma cell numbers in endometrial... 
CD20 | immunohistochemical assay | B-lymphocytes | CD138 | plasma cells | chronic endometritis
Journal Article
Internal Medicine, ISSN 0918-2918, 2018
Solitary plasmacytoma of bone (SBP) tends to progress to multiple myeloma (MM); however, progression to multiple solitary plasmacytomas (MSP) is rare. We... 
multiple myeloma | proteasome inhibitor | plasmacytoma | autologous hematopoietic stem cell transplantation | CD138 | p53
Journal Article
Fertility and Sterility, ISSN 0015-0282, 05/2019, Volume 111, Issue 5, pp. 1002 - 1010.e2
To study the effect of chronic endometritis (CE) diagnosed by CD138 immunohistochemical (IHC) staining on endometrial fibrosis and reproductive prognosis in... 
intrauterine adhesions | CD138 | chronic endometritis | endometrial fibrosis | DIAGNOSIS | HYSTEROSCOPIC ADHESIOLYSIS | PREVALENCE | OBSTETRICS & GYNECOLOGY | WOMEN | REPRODUCTIVE BIOLOGY | IMPLANTATION | RECEPTIVITY | MATRIX-METALLOPROTEINASE-9 | INFERTILITY | OUTCOMES | Viral antibodies | Task forces | Prognosis | Adhesions | Analysis | Fibrosis | Antibodies | Integrins
Journal Article
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, ISSN 1422-0067, 05/2019, Volume 20, Issue 10
Although positron emission tomography (PET) imaging with 18-Fluorodeoxyglucose (F-18-FDG) is a promising technique in multiple myeloma (MM), the development of... 
DARATUMUMAB | SYNDECAN-1 | multiple myeloma | BIOCHEMISTRY & MOLECULAR BIOLOGY | copper-64 | RADIOIMMUNOTHERAPY | ANTIBODY | BIODISTRIBUTION | zirconium-89 | CANCER | CHEMISTRY, MULTIDISCIPLINARY | CETUXIMAB | murine CD138 | EMISSION-TOMOGRAPHY | immuno-PET | EXPRESSION
Journal Article